Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas

BACKGROUND: Despite advances in care, the 5 year overall survival for patients with relapsed and or metastatic sarcoma remains as low as < 35%. Currently, there are no biomarkers available to assess disease status in patients with sarcomas and as such, disease surveillance remains reliant on seri...

Descripción completa

Detalles Bibliográficos
Autores principales: Dao, Long, Ragoonanan, Dristhi, Batth, Izhar, Satelli, Arun, Foglesong, Jessica, Wang, Jian, Zaky, Wafik, Gill, Jonathan B., Liu, Diane, Albert, Aisha, Gordon, Nancy, Huh, Winston, Harrison, Douglas, Herzog, Cynthia, Kleinerman, Eugenie, Gorlick, Richard, Daw, Najat, Li, Shulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695931/
https://www.ncbi.nlm.nih.gov/pubmed/34956881
http://dx.doi.org/10.3389/fonc.2021.760267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695931/
https://www.ncbi.nlm.nih.gov/pubmed/34956881
http://dx.doi.org/10.3389/fonc.2021.760267

Ejemplares similares